Nanjing Hicin Pharmaceutical Co., Ltd. (300584.SZ)

24.74 +0.57 (+2.36%) At close: 03:04PM CST

Nanjing Hicin Pharmaceutical Co., Ltd.

No.1 Hengfa Road
Eco & Tech Dev Zn
Nanjing 210046
China
86 25 8322 2911
https://www.hicin.cn

Sector(s): Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Full Time Employees: 563

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Yuping Cao	GM & Chairman	N/A	N/A	1964
Ms. Qinghua Liu	CFO & Financial Director	N/A	N/A	1970
Ms. Xiaomin Yao	Deputy GM & Director	N/A	N/A	1973
Mr. Yongjun Wang	Deputy GM & Director	N/A	N/A	1965
Mr. Weicheng Liu	Deputy Gen. Mang.	N/A	N/A	1981

Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Nanjing Hicin Pharmaceutical Co., Ltd. engages in the research, development, manufacture, marketing, and sale of pharmaceutical preparations and synthetic chemicals in China. The company offers antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system, and immuno-modulate agents. It also provides technical transferring services. The company also exports APIs; omeprazole sodium and cefepime hydrochloride for injections; and lansoprazole tablets to South-Asian countries, South-American countries, and European countries. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.

Corporate Governance

Nanjing Hicin Pharmaceutical Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.